Heart Rate Control With If Inhibitor, Ivabradine, in Japanese Patients With Chronic Heart Failure : A Randomized, Double-Blind, Placebo-Controlled Phase Ⅱ Study
-
- Tsutsui Hiroyuki
- Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine
-
- Momomura Shinichi
- Cardiovascular Division, Jichi Medical University, Saitama Medical Center
-
- Yamashina Akira
- Department of Cardiology, Tokyo Medical University
-
- Ogawa Hisao
- Department of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University
-
- Shimokawa Hiroaki
- Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine
-
- Kihara Yasuki
- Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical & Health Sciences
-
- Saito Yoshihiko
- First Department of Internal Medicine, Nara Medical University
-
- Hagiwara Nobuhisa
- Department of Cardiology, Tokyo Women’s Medical University
-
- Ito Hiroshi
- Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
-
- Ako Junya
- Cardiovascular Medicine, Kitasato University
-
- Inomata Takayuki
- Cardiovascular Medicine, Kitasato University
-
- Tanaka Takashi
- Clinical Development Planning, Ono Pharmaceutical Co, Ltd
-
- Kawasaki Yasushi
- Clinical Development Planning, Ono Pharmaceutical Co, Ltd
書誌事項
- タイトル別名
-
- Heart Rate Control With I<sub>f</sub> Inhibitor, Ivabradine, in Japanese Patients With Chronic Heart Failure – A Randomized, Double-Blind, Placebo-Controlled Phase II Study –
この論文をさがす
抄録
Background:Elevated heart rate (HR) is an independent risk factor for cardiovascular outcomes in various cardiac diseases, including heart failure (HF).Methods and Results:Randomized placebo-controlled study was conducted to evaluate the effects of ivabradine, an Ifinhibitor, on the resting HR in 126 Japanese symptomatic HF patients with left ventricular ejection fraction ≤35%, resting HR ≥75 beats/min in sinus rhythm, and stable, optimal background treatment. Patients were randomly allocated into 3 groups: placebo; starting dose of ivabradine 2.5 mg twice daily (BID; 2.5 mg group); 5 mg BID group. The dose was increased up to 7.5 mg BID according to dose-adjustment criteria. After the 6-week treatment, the reductions in resting HR were significant in both the 2.5-mg (16.6±8.1 beats/min) and 5-mg (16.4±9.6 beats/min) groups (P<0.0001 for both groups) compared with placebo (1.7±8.7 beats/min). The most frequent side effect of ivabradine was phosphenes, but all were mild. Treatment was discontinued in 1 patient due to HF in the 5 mg group.Conclusions:Ivabradine starting at 2.5 or 5 mg BID effectively reduced resting HR in Japanese HF patients. Ivabradine at the starting dose of 2.5 mg BID could be safer than 5 mg BID. (Circ J 2016; 80: 668–676)
収録刊行物
-
- Circulation Journal
-
Circulation Journal 80 (3), 668-676, 2016
一般社団法人 日本循環器学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390001205108772224
-
- NII論文ID
- 130005128471
-
- NII書誌ID
- AA11591968
-
- ISSN
- 13474820
- 13469843
-
- NDL書誌ID
- 027128193
-
- PubMed
- 26763489
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
- KAKEN
-
- 抄録ライセンスフラグ
- 使用不可